

Announcement No. 4/2010

To NASDAQ OMX Copenhagen

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

14 April 2010

Exiqon A/S – Annual general meeting 2010

The annual general meeting of Exiqon A/S has been held today 14 April 2010 on the Company's address at Skelstedet 16 2950 Vedbaek where the general meeting resolved:

1. To approve the audited annual report,
2. To resolve the appropriation of profit or covering of loss according to the adopted annual report.
3. To re-elect Thorleif Krarup, Erik Walldén, Michael Nobel and Per Wold-Olsen as members of the supervisory board,
4. To re-appoint Deloitte Statsautoriseret Revisionsaktieselskab as the company's auditor, and
5. To amend the Articles of Association as per the decisions by the annual general meeting including authorization to raise capital of the company, grant warrants and change the required number of board members from 5-7 to 3-7.

On a meeting held immediately afterwards the general meeting the supervisory board elected Thorleif Krarup as chairman of the supervisory board and Erik Walldén as vice chairman of the supervisory board. The composition of the supervisory board is, hereafter, as follows:

Thorleif Krarup, chairman
Erik Walldén, vice chairman
Michael Nobel
Per Wold-Olsen

Additional information

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics is developing a series of new molecular diagnostic products based on miRNA. Exiqon's goal is to gain a market-leading position for miRNA-based diagnostics. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

Forward-looking statement:

Certain parts of this release contain forward-looking information with respect to the plans, projections and future performance of the company, each of which involves significant uncertainties. The company's actual results may differ materially from the information set forth in these statements. This is an English translation of the interim report prepared in Danish. In case of any discrepancies between the Danish version and this English translation thereof, the Danish version shall prevail.